Evidence map›Paper›PMID 38549229›Full record

ArticleCancer science2024

Application of prime editing system to introduce TP53 R248Q hotspot mutation in acute lymphoblastic leukemia cell line.

Thao Nguyen, Tomomi Aida, Yuka Iijima-Yamashita, Minori Tamai, Akiko Nagamachi, Keiko Kagami, Chiaki Komatsu, Shin Kasai, Koshi Akahane, Kumiko Goi and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Thao NguyenDepartment of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.ORCID https://orcid.org/0000-0001-5093-167X
Tomomi AidaMcGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Yuka Iijima-YamashitaDepartment of Advanced Diagnosis, Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
Minori TamaiDepartment of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
Akiko NagamachiDepartment of Molecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University, Higashihiroshima, Japan.
Keiko KagamiDepartment of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
Chiaki KomatsuDepartment of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
Shin KasaiDepartment of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
Koshi AkahaneDepartment of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.ORCID https://orcid.org/0000-0001-8591-1281
Kumiko GoiDepartment of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
Toshiya InabaDepartment of Molecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University, Higashihiroshima, Japan.
Masashi SanadaDepartment of Advanced Diagnosis, Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
Takeshi InukaiDepartment of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
University of Yamanashi · JPHiroshima University · JPNagoya Medical Center · JPMcGovern Institute for Brain Research · US

Funding

JSPS JP19H03615JSPS JP22H03037
6 · The paper itself

Abstract

In childhood acute lymphoblastic leukemia (ALL), TP53 gene mutation is associated with chemoresistance in a certain population of relapsed cases. To directly verify the association of TP53 gene mutation with chemoresistance of relapsed childhood ALL cases and improve their prognosis, the development of appropriate human leukemia models having TP53 mutation in the intrinsic gene is required. Here, we sought to introduce R248Q hotspot mutation into the intrinsic TP53 gene in an ALL cell line, 697, by applying a prime editing (PE) system, which is a versatile genome editing technology. The PE2 system uses an artificial fusion of nickase Cas9 and reverse-transcriptase to directly place new genetic information into a target site through a reverse transcriptase template in the prime editing guide RNA (pegRNA). Moreover, in the advanced PE3b system, single guide RNA (sgRNA) matching the edited sequence is also introduced to improve editing efficiency. The initially obtained MDM2 inhibitor-resistant PE3b-transfected subline revealed disrupted p53 transactivation activity, reduced p53 target gene expression, and acquired resistance to chemotherapeutic agents and irradiation. Although the majority of the subline acquired the designed R248Q and adjacent silent mutations, the insertion of the palindromic sequence in the scaffold hairpin structure of pegRNA and the overlap of the original genomic DNA sequence were frequently observed. Targeted next-generation sequencing reconfirmed frequent edit errors in both PE2 and PE3b-transfected 697 cells, and it revealed frequent successful edits in HEK293T cells. These observations suggest a requirement for further modification of the PE2 and PE3b systems for accurate editing in leukemic cells.

Indexed as

Gene EditingMutationPrecursor Cell Lymphoblastic Leukemia-LymphomaTumor Suppressor Protein p53Cell Line, TumorCRISPR-Cas SystemsDrug Resistance, NeoplasmHumansProto-Oncogene Proteins c-mdm2RNA, Guide, CRISPR-Cas SystemsMDM2 protein, humanProto-Oncogene Proteins c-mdm2RNA, Guide, CRISPR-Cas SystemsTP53 protein, humanTumor Suppressor Protein p53acute lymphoblastic leukemiagenome editingprime editing systemTP53 gene mutationtreatment resistance

Identifiers

PMID38549229
PMCPMC11145152
OpenAlexW4393316295

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.